• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis expands COVID-19 research programme with new award
Share
grant award
News

ProAxsis expands COVID-19 research programme with new award

October 13, 2021
-
Posted by Jessica Robinson

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, today announces that it has been awarded funding for a high impact development project from the Northern Ireland Department for the Economy.  The company will immediately initiate the £322,000 project, which will be coordinated via the UK’s innovation agency, Innovate UK as part of the recent Innovate UK SMART Grants competition, to create novel monitoring tools to predict abnormal coagulation in COVID-19 and other illnesses.

Speaking about the project, Dr David Ribeiro, CEO of ProAxsis, commented:

“The impact of the coronavirus pandemic continues to be felt throughout the World.  ProAxsis is keen to continue utilising the company’s unprecedented expertise in active protease biomarkers to maximise the diagnostic and monitoring tools available to the healthcare professionals treating the virus, as well as the researchers seeking to develop new drug treatments.  This grant award will enable us to significantly expand the global understanding of the role of abnormal coagulation in COVID-19.”

Dr Ribeiro added:

“We’re extremely grateful to the NI Department for the Economy for co-funding this critical work, and for supporting the continuing expansion of ProAxsis’ R&D activities in Northern Ireland.”

East Belfast MP Gavin Robinson, commented: “ProAxsis have established themselves as a leader in diagnostics. The Department’s financial commitment to their innovation is a significant sign of confidence in their global leading work. As the world continues to understand, tackle and treat coronavirus, this research will firmly place Belfast at the heart of finding a solution.”

Any enquiries concerning ProAxsis’ work can be directed to info@proaxsis.com.

About ProAxsis

ProAxsis Limited is a global diagnostics company, based in Northern Ireland, with a specific focus on active protease biomarkers. The company currently commercialises activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis. 

This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.  Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months. 

The company has significantly expanded its product portfolio, via the recent in-licensing of a novel bone health assay from the University of Geneva, and a COVID-19 serology assay from AstraZeneca.

In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha.  Grant-funded R&D funded projects for a variety of targets remain a key area of focus.

Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.

October 13, 2021

Related News

Other posts that you should not miss.
News

ProAxsis enhances portfolio with new CE Marked Immunoassay

August 2, 2018
-
Posted by David Ribeiro

ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers …

Read More
August 2, 2018
Posted by David Ribeiro
NEATstik®, News

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

September 4, 2017
-
Posted by Webmaster

ProAxsis Ltd today announces that the company has completed the development process for NEATstik®, a novel point-of-care …

Read More
September 4, 2017
Posted by Webmaster
Announcements, News

ProAxsis and Ulster University initiate new partnership

June 29, 2020
-
Posted by David Ribeiro

ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, has formed a new partnership with Ulster University, the largest university …

Read More
June 29, 2020
Posted by David Ribeiro
← PREVIOUS POST
ProAxsis makes significant progress towards measuring bone health with a new innovation for patients at high risk of osteoporotic fractures
NEXT POST →
ProAxsis presents exciting new data at the ERS International Congress 2021
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis expands COVID-19 research programme with new award - ProAxsis